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ABSTRACT
Hydroxychloraquine-induced acute psychotic disorder in a female patient with 
rheumatoid arthritis: a case report
Chloroquine and its derivative hydroxychloroquine (HCQ) have been used for acute and prophilactic 
treatment of malaria for most of the last century. HCQ has anti-inflammatory, antilipidemic and antithrombotic 
effects and in recent years has become an important drug for treating rheumatoid arthritis (RA). In the 
literature, antimalarial-induced psychosis has been reported in a small number of cases; however, we did not 
find any case related with HCQ-induced psychosis in rheumatoid arthritis. We want to report a 73-year-old 
female RA patient without a previous history of psychosis who developed psychosis after use of HCQ. HCQ 
is being increasingly prescribed in autoimmune diseases. Clinicians need to be aware of psychosis as a rare 
but debilitating side effect.
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ÖZET
Romatoid artriti olan kadın hastada hidroksiklorokin kullanımına bağlı gelişen akut 
psikotik bozukluk: Olgu sunumu
Klorokin ve ondan sentez edilen hidroksiklorokin (HCQ) sıtmanın akut ve idame tedavisinde son yüzyılda 
yaygın olarak kullanılmaktadır. HCQ’nin antiinflamatuvar, antilipidemik ve antitrombotik etkileri vardır ve son 
yıllarda romatoid artrit tedavisinde önemli hale gelmiştir. Yazında antimalaryal kullanımına bağlı psikoz 
birkaç vaka sunumunda bildirilmiş fakat romatoid artritte HCQ kullanımına bağlı bir olguya rastlanmamıştır. 
Bu olgu sunumunda psikoz öyküsü olmayan 73 yaşında RA’i olan yaşlı kadın hastada HCQ kullanımına bağlı 
gelişen psikoz vakasını sunduk. HCQ otoimmün hastalıkların tedavisinde yaygın olarak reçete edilmeye 
başlanmıştır. Klinisyenlerin nadir ancak işlevselliği bozan bir yan etki olan psikoz konusunda uyanık olmaları 
gerekmektedir.
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INTRODUCTION
Besides acute and maintenance treatment of malaria, 4 -Aminoqu ino lones  ( ch lo roqu ine  and 
hydroxychloroquine) are also frequently used for the 
treatment of immune diseases such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE), 
as well as extraintestinal amebiasis. Absence of serious 
adverse events other than on the field of vision, 
presence of antithrombic and antilipidemic efficacy in 
addition to anti-inflammatory efficacy, being cheap 
and well tolerated compared to the other drugs, and a 
fast onset of action are the main reasons for preferring 
these drugs (1,2). Despite widespread usage in regions 
where malaria is endemic, toxic dose range and mental 
and behavioral side effects of these drugs are not 
known definitely. 
 Maximum plasma concentration after single dose is 
reached in one to two hours, its half-life being as much 
as 3-6 days (average five days). High concentration 
occurs in the liver, spleen, kidneys, lungs, and brain 
and spinal cord. Elimination half-life ranges between 2 
and 3 days in plasma to over 300 hours in tissues (3,4). 
Potential side effects include central nervous system 
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involvement, such as headache, neuropathy, vertigo, 
depression, psychosis and mania, neuromuscular 
system-related symptoms such as myopathy, loss of 
sensation and atrophy in the proximal muscles, and 
dermatological reactions such as hair loss, pruritus, 
pigmentation and skin rashes (2). Although the 
incidence of serious neuropsychiatric adverse events 
has not been definitely established, they have been 
reported to occur at a rate of approximately 1:136005. 
It is thought that these adverse events result from 
idiosyncratic drug reactions (6,7), and female gender is 
stated to be a risk factor (8).
 Neuropsychiatric adverse events reported in the 
literature are generally those associated with the use of 
antimalarial drugs in malaria. However, we 
encountered no study highlighting side effects of these 
drugs when used in the treatment of RA, for which 
they recently have been widely used because of their 
anti-inflammatory efficacy. 
 With this case report, we aimed to discuss a 
psychotic disorder due to hydroxychloroquine-use in a 
geriatric patient who was being followed for 
rheumatoid arthritis, as well as to attract the clinicians’ 
attention to this subject by scrutinizing side effects of 
chloroquine in this context. 
 CASE 
 We present the case of a 73-year-old illiterate 
woman with five children. She consulted an internal 
medicine-rheumatology specialist approximately a 
month ago for joint pain in wrist and knee; she was 
diagnosed with RA attack and recommended to 
receive hydroxychloroquine at a dose of 400mg/day. 
She was brought to our psychiatry policlinic by her 
relatives due to the development of symptoms such as 
repeating the same sentences, meaningless speech, 
hearing voices, seeing things, not recognizing the 
people around her, crying for no reason, contraction in 
the body, inability to swallow solid/fluid foods, 
inability of speaking, and sometimes shouting. 
Symptoms had developed after the 5th day of 
treatment. Her history revealed that she had been 
treated for RA for about 25 years, receiving various 
medications such as sulfasalazine, methotrexate, and 
corticosteroids, and had had no psychiatric complaints 
during that period. On mental examination of the 
patient, who was brought in a wheelchair because of 
difficulty in walking, her appearance was consistent 
with her age but self-care was decreased, and she was 
awake with somewhat retarded association of ideas. 
Thought content and memory could not be evaluated. 
Her mood was agitated. Her perception included 
visual and auditory hallucinations. Orientation to 
place, time and person was correct. Expressed 
behaviors included meaningless shouting, fearful facial 
expression and looking at different sides of the room 
with sudden reactions. No mental disorder was 
determined in personal and family histories. Her 
medical history is significant for diabetes mellitus, and 
insulin was used for treatment. In her neurologic 
examination, no focal changes or motor or sensory 
symptoms were found.
 Dementia, delirium and central involvement of RA 
were considered in differential diagnosis of the patient. 
Psychiatric side effects in RA patients are also 
associated with increased functional disability, drugs 
or pain. Therefore, central involvement due to RA were 
excluded. The presentation of delirium was considered 
in differential diagnosis but excluded because of the 
absence of any reason that might explain this situation 
in organic examination, complete orientation, and 
absence of diurnal rhythm. Alzheimer dementia was 
also excluded based on her relative’s anamnesis 
revealing that her cognitive functions were normal 
before the onset of these complaints. Vascular 
dementia can occur suddenly after a stroke, and 
symptoms can vary widely, depending on the severity 
of the blood vessel damage and the part of the brain 
affected. The core features of dementia with Lewy 
bodies are behavioral disturbances, detailed recurrent 
and well-formed visual hallucinations, fluctuations in 
cognitive performance, motor Parkinsonism, and the 
presence of Lewy bodies in the brain. Frontotemporal 
dementia was excluded because of the absence of 
dramatic changes of personality, impulsiveness or 
emotional indifference, progressive aphasia, or social 
withdrawal. Mini Mental Test could not be performed 
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because of limited communication with the patient. 
 Computed tomography of the brain and laboratory 
analyses were within the normal ranges. A Structured 
Clinical Interview for DSM-IV Axis I disorders (SCID-I) 
was performed with the patient after recovery from 
agitation on the 3rd day of psychiatric treatment (9,10). 
She was diagnosed with drug-induced psychotic 
disorder. Her Clinical Global Impressions-Severity of 
Illness Scale (CGI-S) (11) score at baseline was 6 
(severely ill). Hydroxychloroquine was discontinued 
and the already restricted fluid intake was supported 
with intravenous fluid replacement. Intramuscular 
diazepam was injected for the contractions in her body 
and olanzapine was commenced at a dose of 5mg/day 
via oral route. On the 3rd day of treatment, the patient’s 
stabilized emotional state was observed, as aggression 
and uneasiness disappeared. On the 5th day of 
treatment, restored sleep and appetite and good insight 
were observed, The psychotic picture completely 
improved approximate ly  one  week a f te r 
discontinuation of hydroxychloroquine. Her CGI-S 
score at this point was 1 (normal, not at all ill), CGI-
Improvement Scale score was 1 (very much improved). 
The score of the Mini Mental Test performed in that 
period was 27/30. Olanzapine therapy was 
discontinued. Her symptoms did not recur within a 
2-month follow-up period. 
 DISCUSSION 
 Psychotic signs and symptoms may appear not 
only in schizophrenia and similar disorders, but also 
over the course of other psychiatric and neurological 
disorders. In addition, drugs such as glucocorticoids 
and other steroids, anticholinergic drugs, L-Dopa, H2 
receptor blockers, digitalis, antabuse, quinolones, 
selegiline, isoniazid and topiramate, toxins, and 
substances such as LSD and cocaine may lead to a 
similar picture (12). 
 Chloroquine and hydroxychloroquine were 
developed in 1934 by German scientists and have been 
used in the treatment of inflammatory diseases such as 
malaria, RA and SLE since 1944 (13). The most 
common side effects of hydroxyquinolines are 
encountered in the field of vision. However, drug-
related neuropsychiatric adverse events are rare 
(1:13600) (5). Although the mechanisms of such 
adverse events are not clear, some hypotheses have 
been suggested. It is thought that chloroquine enhances 
turnover of dopamine transporter protein, inhibits 
dopaminergic and muscarinic-cholinergic receptors by 
decreasing the number of postsynaptic dopamine 
receptors, and thereby shows anticholinergic efficacy. 
Another hypothesis states that chloroquine behaves as 
a strong serotonin reuptake inhibitor, inhibiting 
serotonin transporter protein. Telgt et al. (14) suggested 
another explanation, according to which antimalarials 
may have the same pathologic activity as quinolines in 
acting as N-methyl-d-aspartate agonists and gamma-
aminobutyric acid antagonists. Another mechanism 
considered for the explanation of neuropsychiatric 
adverse events is the drug’s probability of decreasing 
the cortical flow of information by inhibiting P 
glycoprotein (7). 
 A great variety of psychiatric side effects, such as 
mania, depression, visual and auditory hallucinations, 
delusions of persecution/grandiosity, agitation, suicidal 
ideation/suicide, and insomnia have been reported due 
to chloroquine use. These adverse events are dose-
independent and may appear approximately within 2 
hours or 40 days. They generally disappear within one 
week following discontinuation of the drug (6,15-17). 
In their review, Mohan et al. reported chloroquine-
induced psychiatric adverse events in at least 10 cases 
between 1978 and 1980. The mentioned symptoms 
appeared between the third and 10th day after starting 
chloroquine use and disappeared within 1-2 weeks 
following discontinuation of drug (6). Bhatia et al. (16)
used chloroquine and evaluated six cases that developed 
psychiatric adverse events. They reported that 70% of 
the patients were female and that adverse events 
appeared between the 2nd and 7th day after the onset of 
treatment independently of the dose and the way of its 
administration (before/after meals). They determined 
organic psychosis in 32, schizophrenia-like disorder in 
12, mania in four, and anxiety or depressive disorder in 
eight cases (16). Using a database, Meier et al. (15) 
reviewed 35370 patients that had used antimalarial 
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drug between 1990 and 1999 in England and 
determined that 45.2% of the cases were male and 505 
patients had depression, 16 patients had psychosis, 
and 57 patients had panic attack. They emphasized 
that the risk of psychosis and panic attack due to 
overall antimalarial drugs (mefloquine, chloroquine, 
proguanil, and doxycycline) is significantly lower 
compared to other psychiatric disorders (15).
 In the present case, which had no personal or family 
history of psychiatric disorder, agitation, auditory and 
visual hallucinations, perseveration, and impairment of 
the eating routine appeared on the 5th day after 
chloroquine use, which is consistent with the literature. 
She was diagnosed with hydroxychloroquine-induced 
psychotic disorder, and drug therapy was discontinued. 
It was observed that the symptoms improved 
approximately one week later and did not recur 
subsequently. Because of the absorption, metabolism, 
and excretion features of HCQ, the patient’s symptoms 
may occur after 5 days of treatment and disappear one 
week after discontinuation of the treatment. 
 Another point worth mentioning is that the patient, 
while having used antimalarial medication previously, 
had not developed any psychiatric disorder so far. 
Many factors such as age, multiple health problems 
requiring polypharmacy as well as changes in 
pharmacokinetics and pharmacodynamics in elderly 
patients may result in an increased incidence of drug 
toxicity and adverse drug reactions. In elderly people, 
due to the amount of water in the body decreasing and 
fat tissue increasing, lipophilic drugs such as HCQ are 
more easily stored in fat tissues. In addition, elderly 
arthritic patients may have raised levels of HCQ due to 
reduced renal clearance (18). Because of all these age-
related changes, age may have been responsible for 
psychiatric side effects in this patient. 
 It is important to question the psychiatric history of 
the patient in detail, keeping a record of the psychiatric 
disorders that might develop with chloroquine use in 
the treatment of compelling diseases such as RA, SLE 
and malaria, to be alert for potential adverse events 
particularly in old and female patients, and to adjust 
the dose slowly and gradually. Considering that 
4-Aminoquinolones are frequently being used in 
regions where malaria is endemic, while at the same 
time offering a good therapeutic option in some other 
diseases and have a low cost, it is obvious that these 
drugs should be known better. Scientific studies and 
case reports are needed particularly on their usage in 
extra-malarial diseases.
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